Delayed Clinical Response to Adalimumab in Patients with Crohn’s Disease

Crohn’s disease (CD) is a long-term condition that causes inflammation in the digestive system, leading to symptoms such as severe stomach pain, diarrhea, weight loss, and fatigue. It is a chronic illness, meaning it persists over time and can affect a person's quality of life. Many people with CD are treated with medications such as corticosteroids (a class of anti-inflammatory medications used to treat various conditions, including CD to reduce inflammation), immune system-modulating drugs (medications that influence the immune system by suppressing or stimulating it), or biologics (a class of drugs that are produced using a living system, administered via injection or infusion)- but not all patients respond well to these treatments. This creates a need for better treatments and ways to personalize care for each patient.

One medication that has shown promise in treating CD is adalimumab, which works by targeting certain molecules in the immune system to reduce inflammation. Although it helps many patients feel better by the 12th week of treatment, some people take longer to see improvements. These individuals are referred to as “delayed responders.” Understanding why some people respond more slowly to treatment could help doctors decide on the best course of action, ensuring that patients receive the most effective care.

The goal of this research is to identify factors that could explain why some patients are delayed responders to adalimumab. This could include genetic markers, previous treatments, or other health conditions. By understanding these characteristics, we can improve how doctors predict which patients are more likely to benefit from this treatment and adjust their treatment plans accordingly.

This is a post-hoc analysis of patient-level clinical trial data from the SERENE study. Response to treatment over time will be compared among those who respond quickly and those who take longer to respond. This comparison will help us identify patterns and factors that might influence how well a patient responds to the medication.

Ultimately, the findings from this research could lead to better treatment strategies for CD, ensuring that patients get the right medication at the right time and improve their chances of feeling better faster.